Six-month report January-June 2013 April–June Net

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 28, 2013 at 3:30 AM

Six-month report January-June 2013

April–June · Net sales rose by 92% to SEK 2,200k (1,148k). · Loss after financial items was SEK 3,903k (loss: 4,430k). · Comprehensive income was a loss of SEK 3,852k (loss: 4,392k). · Comprehensive income per share basic and diluted totaled SEK -0.27 (-0.53). · Cash flow from operating activities during the period was SEK -3,251k ( -4,474k). · Cash and cash equivalents at the end of the period amounted to SEK 10,851k (14,772k). · The rights issue in April raised about SEK 13.8 million before issue expenses for Genovis. · Genovis and the wholly owned subsidiary GeccoDots are moving to new premises in Medicon Village, Lund, in September. January - June · Net sales rose by 96% to SEK 4,106k (2,092k). · Loss after financial items was SEK 7,860k (loss: 8,438k). · Comprehensive income was a loss of SEK 7,799k (loss: 8,363k). · Comprehensive income per share basic and diluted totaled SEK -0.60 (-1.10). · Cash flow from operating activities during the period was SEK -7,680k ( -7,356k). Events after the end of the period Genovis signed an agreement with Respiratorius to test and evaluate RESP-3000 as a new biomarker for early diagnosis of cardiovascular disease using a “PET” camera. Genovis is coordinating the work, but GeccoDots AB, Genovis’ wholly owned subsidiary, will conduct the final evaluation. The evaluation is expected to be completed in late 2013 or early 2014. The agreement includes the option for Genovis to acquire technology and patents relating to RESP-3000 in preclinical applications and Genovis intends to initiate negotiations for an acquisition if the tests show favorable results. Comments from CEO Sarah Fredriksson We continued to prioritize meetings with clients during the spring. This strategy produces results and during the second quarter sales jumped 92%, number of orders rose by 36% and the average order value was up 42% compared with last year. An analysis of individual orders shows that the increase in number of orders is mainly attributable to new customers, while established customers account for the increase in volume per order. The number of publications and presentations at conferences featuring our products continue to grow. The FDA, Pfizer, and Bruker were among the participants at the American Society for Mass Spectrometry’s annual meeting in early June who featured methods and results based on the use of FabRICATOR. Marketing activities will hopefully yield long -term results, even if in the short-term they require an investment in staff, webinars, workshops, and an increased number of conferences and meetings. The results for the second quarter and the first six months of the year improved somewhat compared with 2012. It is encouraging to see that our persistent long -term efforts are effective, although we have a ways to go before the protein engineering portfolio generates a positive result. To achieve this objective we will develop our business to include commercial production at the customer. Sales today are generated by products that the customer uses to screen new candidates, in production development and in preclinical development. Our primary goal for 2013 is to continue to achieve robust sales growth. In September and October we will therefore launch two products in the protein engineering portfolio. Earlier product launches in the protein engineering portfolio have been well-received by existing customers and sales of smaller test volumes usually take off quickly. During the autumn our subsidiary GeccoDots will also introduce itself to the market and the first product will be launched in September. Lund in August Sarah Fredriksson For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 sarah.fredriksson@genovis.com ABOUT GENOVIS Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: 46 (0)31-745 50 00

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...